Showing 2911-2920 of 6036 results for "".
- Largest Study on Children’s Soft Contact Lens Wear Safety Shows Very Low Complication Rateshttps://modernod.com/news/largest-study-on-childrens-soft-contact-lens-wear-safety-shows-very-low-complication-rates/2478654/The largest retrospective study of its kind has found very low complication rates in children who wear soft contact lenses, similar to rates in adults.1 The
- NextGen Launches a Dedicated Optometric Workflow in its Fully Integrated Eye Care Platformhttps://modernod.com/news/nextgen-launches-a-dedicated-optometric-workflow-in-its-fully-integrated-eye-care-platform/2478643/NextGen Healthcare announced it has launched a dedicated optometric workflow in its fully integrated eye care platform. This new optometric software solution is part of the NextGen Ophthalmic Suite, which integrates b
- Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies in Ophthalmic Diseaseshttps://modernod.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and
- InMed Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoidshttps://modernod.com/news/inmed-licenses-midrops-delivery-technology-from-eyecro-for-the-delivery-of-therapeutic-cannabinoids/2478621/InMed Pharmaceuticals announced that it has secured an exclusive, worldwide license from EyeCRO for its Microemulsion Drug Ocular Penetration System (MiDROPS) eyedrop delivery technology targeting effective, topical administration of cannabinoids to the eye. EyeCRO is a contract research o
- TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative-Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucomahttps://modernod.com/news/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma/2478608/TearClear announced successful completion of pre-IND (investigational new drug) meeting with the FDA regarding the development plan for the preservative-free multi-dose delivery of a proprietary latanoprost formulation, including the clinical study design for the registration
- When Coronavirus Vaccines Are Ready, Dentists, Optometrists May Give Shotshttps://modernod.com/news/when-coronavirus-vaccines-are-ready-dentists-optometrists-may-give-shots/2478599/With multiple COVID-19 vaccines rapidly heading toward approval, optometrists and dentists are pushing for the authority to immunize patients during routine eye exams and dental cleanings. These medical professionals say their help will be needed to distribute the vaccines
- Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027https://modernod.com/news/report-dry-eye-treatment-devices-market-size-worth-400-8-million-by-2027/2478591/The global dry eye treatment devices market size is estimated to reach US$400.8 million by 2027, expanding at a CAGR of 6.4%, according to a new report by Grand View Research, Inc. The increasing demand for targeted, noninvasive, faster, and patient compliant treatment methods to alleviate dry ey
- Doctors Report Patients’ Health Declining Due to Delayed or Inaccessible Care During COVID-19 Pandemichttps://modernod.com/news/doctors-report-patients-health-declining-due-to-delayed-or-inaccessible-care-during-covid-19-pandemic/2478581/Patients’ overall health continues to suffer due to the pandemic, with the majority of primary care physicians reporting that their patients’ mental health has declined during the past 8 months, according to a FierceHealthcare
- Despite Impressive Data, FDA’s Coronavirus Vaccine Reviews Will Take Weeks, Not Days, Official Sayshttps://modernod.com/news/despite-impressive-data-fdas-coronavirus-vaccine-reviews-will-take-weeks-not-days-official-says/2478574/As leading COVID-19 vaccines post positive phase 3 data and near FDA submissions, the agency official in charge of reviewing vaccines is emphasizing transparency and patience during the high-stakes process, according to a FiercePharma
- One Year After FDA Approval, MiSight 1 Day Contact Lens Mainstreams Myopia Management in the U.S.https://modernod.com/news/one-year-after-fda-approval-misight-1-day-contact-lense280a8-mainstreams-myopia-management-in-the-u-s-e280a8e280a8/2478564/Today, CooperVision celebrates 1 year since MiSight 1 day became the first and only FDA approved contact lens for slowing the progression of myopia in children ages 8-12. The milestone and subsequent efforts have vaulted myopia management into mainstream eye care in the United States, including w